Inactive Instrument

Analyst Reco. POIT BIOP

Equities

RACA

US7305411099

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Brookline Capital Downgrades POINT Biopharma Global to Hold From Buy, Cuts Price Target to $12.50 From $27	21/12	MT
Piper Sandler Downgrades POINT Biopharma Global to Neutral From Overweight, Price Target is $12.50	24/23/24	MT
Raymond James Downgrades POINT Biopharma to Market Perform From Outperform, Trims Price Target to $12.50 From $13	06/23/06	MT
JonesTrading Downgrades POINT Biopharma Global to Hold From Buy	04/23/04	MT
Truist Securities Downgrades POINT Biopharma Global to Hold From Buy, Adjusts Price Target to $12.50 From $13	03/23/03	MT
William Blair Downgrades POINT Biopharma Global to Market Perform From Outperform	03/23/03	MT
Piper Sandler Cuts Price Target on POINT Biopharma Global to $12.50 From $16, Maintains Overweight Rating	03/23/03	MT
JonesTrading Cuts Price Target on POINT Biopharma Global to $12.50 From $18, Maintains Buy Rating	03/23/03	MT
What high rates mean for our favorite stocks	03/23/03
Oppenheimer Adjusts POINT Biopharma Global Price Target to $13 From $15, Maintains Outperform Rating	28/23/28	MT
Raymond James Initiates POINT Biopharma With Outperform Rating, Price Target is $10	14/22/14	MT
SVB Securities Initiates POINT Biopharma Global With Outperform Rating, Sets Price Target at $14	30/22/30	MT
Truist Securities Cuts Price Target on POINT Biopharma Global to $14 From $22, Maintains Buy Rating	15/22/15	MT
Berenberg Bank Adjusts POINT Biopharma Global Price Target to $18 From $20, Maintains Buy Rating	15/22/15	MT
Oppenheimer Initiates POINT Biopharma Global With Outperform Rating, $20 Price Target	11/22/11	MT
Piper Sandler Adjusts Price Target on POINT Biopharma Global to $17 From $19, Reiterates Overweight Rating	19/22/19	MT
Truist Securities Starts POINT Biopharma Global at Buy With $22 Price Target	16/22/16	MT
Berenberg Bank Initiates Coverage on POINT Biopharma Global With Buy Rating, $20 Price Target	14/22/14	MT
Guggenheim Raises POINT Biopharma Global's Price Target to $22 From $20, Maintains Buy Rating	12/22/12	MT
Piper Sandler Raises POINT Biopharma Global's Price Target to $19 From $14, Maintains Overweight Rating	12/22/12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. POIT BIOP

Equities

RACA

US7305411099

Analyst Reco.

Filters